NVS
Novartis AG ADR
NYSE: NVS · HEALTHCARE · DRUG MANUFACTURERS - GENERAL
$142.94
-1.76% today
Updated 2026-04-29
Market cap
$280.79B
P/E ratio
20.32
P/S ratio
4.96x
EPS (TTM)
$7.16
Dividend yield
3.26%
52W range
$102 – $165
Volume
2.1M
WallStSmart proprietary scores
51
out of 100
Grade: C
Hold
Investment rating
4.0
Growth
C5.5
Quality
C+9.0
Profitability
A+3.3
Valuation
D4/9
Piotroski F-Score
Moderate
2.0
Altman Z-Score
Grey zone
—
Industry rank
—
View all highly rated stocks (75+) →201 stocks currently score above 75
Price targets
Analyst target
$153.26
+7.22%
12-Month target
$131.02
-8.34%
Intrinsic (DCF)
$109.78
Margin of safety
-52.22%
2 Strong Buy2 Buy5 Hold2 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ Profit margin 24.70% — above average
+ ROE 30.80% — strong efficiency
+ Free cash flow $1.64B — positive
Risks
- 52.22% above intrinsic value
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM | 2026 (E) |
|---|---|---|---|---|---|---|
| Revenue | $43.46B | $46.66B | $51.72B | $54.81B | $56.67B | $58.0B |
| Net income | $6.96B | $14.85B | $11.94B | $14.06B | $2.41B | — |
| EPS | — | — | — | — | $7.16 | $8.97 |
| Free cash flow | $11.56B | $11.71B | $13.80B | $17.69B | $1.64B | — |
| Profit margin | 16.00% | 31.83% | 23.09% | 25.64% | 24.70% | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2020-07-14 | NOVARTIS, PHARMA AG | Sale | 7,367,387 | — |
| 2020-07-14 | NOVARTIS, PHARMA AG | Buy | 5,908,089 | — |
| 2020-06-30 | NOVARTIS, BIOVENTURES LTD | Sale | 199,996 | — |
Peer comparison
Smart narrative
Novartis AG ADR trades at $142.94. representing a P/E of 20.32x trailing earnings. Our Smart Value Score of 51/100 indicates the stock is fair. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of 1.96, it sits in the grey zone. TTM revenue stands at $56.67B. with profit margins at 24.70%. Our DCF model estimates intrinsic value at $109.78.
Frequently asked questions
What is Novartis AG ADR's stock price?
Novartis AG ADR (NVS) trades at $142.94.
Is Novartis AG ADR overvalued?
Smart Value Score 51/100 (Grade C, Hold). DCF value $109.78.
What is the price target of Novartis AG ADR (NVS)?
The analyst target price is $153.26, representing +7.2% upside from the current price of $142.94.
What is the intrinsic value of Novartis AG ADR (NVS)?
Based on our DCF model, intrinsic value is $109.78, a -52.2% margin of safety versus $142.94.
What is the future stock price of NVS by 2030?
Our research-backed model estimates Novartis AG ADR could reach $145.47 by 2030, based on analyst consensus, management guidance, and sector analysis.
What is Novartis AG ADR's revenue?
TTM revenue is $56.67B.
Piotroski F-Score?
4/9 — moderate financial health.
Altman Z-Score?
1.96 — grey zone.
Company info
SectorHEALTHCARE
IndustryDRUG MANUFACTURERS - GENERAL
CountryUSA
ExchangeNYSE
CurrencyUSD
Quick metrics
P/S ratio4.96x
ROE30.80%
Beta0.52
50D MA$156.00
200D MA$136.92
Shares out1.91B
Float1.82B
Short ratio—
Avg volume2.1M
Performance
1 week-3.08%
1 month-6.42%
3 months-4.01%
YTD+3.68%
1 year—
3 years—
5 years—